Silo Pharma (SILO) Non Operating Income (2018 - 2026)
Silo Pharma (SILO) posted Non Operating Income of -$52457.0 for Q1 2026, up 44.79% sequentially from -$95006.0 in Q4 2025, and down 183.68% YoY from $62684.0 in Q1 2025.
Silo Pharma (SILO) Non Operating Income (2018 - 2026) Analysis & Trends
Silo Pharma has reported Non Operating Income for 9 years, with the latest figure at -$52457.0 in Q1 2026.
- Quarterly Non Operating Income fell 183.68% year-over-year to -$52457.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$62177.0 (down 120.89% YoY) and the FY2025 annual result came in at $52964.0, down 83.07% from the prior year.
- Non Operating Income improved to -$52457.0 in Q1 2026 per SILO's latest filing, from -$95006.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $113238.0 in Q3 2023 and troughed at -$164117.0 in Q2 2022.
- A 5-year average of $15182.2 and a median of $44258.0 in 2025 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income sank 441.61% in 2022, then soared 2009.55% in 2023.
- Over 5 years, Non Operating Income stood at -$5873.0 in 2022, then jumped by 2009.55% to $112148.0 in 2023, then declined by 26.23% to $82732.0 in 2024, then sank by 214.84% to -$95006.0 in 2025, then surged by 44.79% to -$52457.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$52457.0, -$95006.0, and $41028.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Silo Pharma | 2.92 Mn | 2.92 Mn | - | 96,120.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 96,120.00 |
| Mar 31, 2026 | -52,457.00 |
| Dec 31, 2025 | -95,006.00 |
| Sep 30, 2025 | 41,028.00 |
| Jun 30, 2025 | 44,258.00 |
| Mar 31, 2025 | 62,684.00 |
| Dec 31, 2024 | 82,732.00 |
| Sep 30, 2024 | 81,241.00 |
| Jun 30, 2024 | 70,995.00 |
| Mar 31, 2024 | 77,846.00 |
| Dec 31, 2023 | 112,148.00 |
| Sep 30, 2023 | 113,238.00 |
| Jun 30, 2023 | 102,034.00 |
| Mar 31, 2023 | -102,911.00 |
| Dec 31, 2022 | -5,873.00 |
| Sep 30, 2022 | -34,092.00 |
| Jun 30, 2022 | -164,117.00 |
| Mar 31, 2022 | -75,650.00 |
| Dec 31, 2021 | -114,629.00 |
| Sep 30, 2021 | 6.96 Mn |